How much cash does Stoke Therapeutics, Inc. generate?

Stoke Therapeutics, Inc. (STOK) generated $26.4M in operating cash flow over the trailing twelve months.

What is Stoke Therapeutics, Inc.'s free cash flow?

After $871.0K of capital expenditures, Stoke Therapeutics, Inc.'s free cash flow was $25.8M over the trailing twelve months, up 132.0% year over year.

Where does Stoke Therapeutics, Inc.'s cash flow data come from?

Every line is extracted from Stoke Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Stoke Therapeutics, Inc. STOK Cash Flow Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net income	-$169.77M-2,366%	-$6.89M-117%	$40.57M-22.7%	$52.48M+4.4%	$50.27M+156%
Depreciation and amortization	$1.73M-2.1%	$1.77M-6.4%	$1.89M-4.9%	$1.99M-4.9%	$2.09M-4.0%
Stock-based compensation	$34.24M+6.2%	$32.24M+9.2%	$29.53M+1.9%	$28.98M+0.6%	$28.81M+4.9%
Change in accounts receivable	——	——	——	——	$1.36M+2,625%
Change in other assets	——	——	——	——	——
Change in deferred revenue	——	——	-$25.58M-3.9%	-$24.62M-40.3%	-$17.54M+40.3%
Net cash from operating activities	——	——	——	——	$69.54M+180%
Capital expenditures	$871K+30.0%	$670K+39.6%	$480K+6.4%	$451K+31.5%	$343K+69.0%
Net cash from investing activities	-$158.84M+18.9%	-$195.91M-45.3%	-$134.85M+18.2%	-$164.85M-57.5%	-$104.65M+3.4%
Proceeds from issuance of common stock	$10.8M+25.6%	$8.6M+86.5%	$4.61M+104%	$2.26M-8.6%	$2.48M+43.8%
Net cash from financing activities	$180.34M+85.2%	$97.39M+1,634%	$5.62M-47.3%	$10.66M-91.9%	$130.75M-0.3%
Net increase (decrease) in cash	-$117.06M-162%	-$44.66M+32.8%	-$66.47M+27.6%	-$91.78M-195%	$96.46M+253%
Depreciation	$1.73M-2.1%	$1.77M-6.4%	$1.89M-4.9%	$1.99M-4.9%	$2.09M-4.0%
Increase Decrease In Accounts Payable Accrued Liabilities And Opertaing Leases	$829K-96.1%	$21.29M+46.2%	$14.57M—	——	——
Deferred revenue	——	——	-$25.58M-3.9%	-$24.62M-40.3%	-$17.54M+40.3%
Increase (Decrease) in Prepaid Expense and Other Assets	——	——	——	——	——
Reduction In Carrying Amount Of Operating Lease Right Of Use Assets	$2.42M+0.4%	$2.41M+2.9%	$2.34M-1.0%	$2.36M+2.2%	$2.31M+2.2%
Proceeds From Controlled Equity Offering Sales Agreement Net Of Commissions	——	$87.78M+28.9%	$68.08M+40.7%	$48.37M+68.8%	$28.66M+220%
Proceeds From Issuance Of Common Stock In Controlled Equity Offering Sales Agreement	——	——	——	——	——
Proceeds from issuance of common stock relating to employee stock plans	——	——	——	——	——
Accrued payables for capital expenditures	$789K+63.7%	$482K+239%	$142K+26.8%	$112K+36.6%	$82K+34.4%
Free cash flow	——	——	——	——	$69.2M+179%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Stoke Therapeutics, Inc..

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

How much cash does Stoke Therapeutics, Inc. generate?: Stoke Therapeutics, Inc. (STOK) generated $26.4M in operating cash flow over the trailing twelve months.
What is Stoke Therapeutics, Inc.'s free cash flow?: After $871.0K of capital expenditures, Stoke Therapeutics, Inc.'s free cash flow was $25.8M over the trailing twelve months, up 132.0% year over year.
Where does Stoke Therapeutics, Inc.'s cash flow data come from?: Every line is extracted from Stoke Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.